Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Chase

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2011
Aberrations of EZH2 in cancerAndrew Chase, Nicholas C P Cross
Clinical Science (London, England : 1979)|September 12, 2006
Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinasesAndrew Chase, Nicholas C P Cross
Acta Haematologica|March 29, 2002
Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemiaJaspal Kaeda, Andrew Chase, John M Goldman
BMJ Case Reports|March 7, 2024
Passenger lymphocyte syndrome following minor ABO-mismatched liver transplantationAkash Mathavan, Urszula Krekora, Andrew Chase Kleehammer, et al.
Blood|August 19, 2007
Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndromeAndrew Chase, Francis H Grand, Nicholas C P Cross
Clinical and Vaccine Immunology : CVI|January 13, 2012
Evaluation of biological sample preparation for immunosignature-based diagnosticsBrian Andrew Chase, Stephen Albert Johnston, Joseph Barten Legutki
Haematologica|August 10, 2012
Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndromeAndrew Chase, Catherine Bryant, Joannah Score, et al.
Leukemia Research|May 26, 2009
A high-throughput candidate gene mutation screen in lymphoproliferative and myeloproliferative neoplasiasSebastian Kreil, Andreas Hochhaus, Nicholas C P Cross, et al.
Cells|July 12, 2020
EZH2 in Myeloid MalignanciesJenny Rinke, Andrew Chase, Nicholas C P Cross, et al.
Experimental Hematology|September 4, 2007
A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapyFrancis H Grand, Sameena Iqbal, Lingyan Zhang, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2011
Aberrations of EZH2 in cancerAndrew Chase, Nicholas C P Cross
Clinical Science (London, England : 1979)|September 12, 2006
Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinasesAndrew Chase, Nicholas C P Cross
Acta Haematologica|March 29, 2002
Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemiaJaspal Kaeda, Andrew Chase, John M Goldman
BMJ Case Reports|March 7, 2024
Passenger lymphocyte syndrome following minor ABO-mismatched liver transplantationAkash Mathavan, Urszula Krekora, Andrew Chase Kleehammer, et al.
Blood|August 19, 2007
Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndromeAndrew Chase, Francis H Grand, Nicholas C P Cross
Clinical and Vaccine Immunology : CVI|January 13, 2012
Evaluation of biological sample preparation for immunosignature-based diagnosticsBrian Andrew Chase, Stephen Albert Johnston, Joseph Barten Legutki
Haematologica|August 10, 2012
Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndromeAndrew Chase, Catherine Bryant, Joannah Score, et al.
Leukemia Research|May 26, 2009
A high-throughput candidate gene mutation screen in lymphoproliferative and myeloproliferative neoplasiasSebastian Kreil, Andreas Hochhaus, Nicholas C P Cross, et al.
Cells|July 12, 2020
EZH2 in Myeloid MalignanciesJenny Rinke, Andrew Chase, Nicholas C P Cross, et al.
Experimental Hematology|September 4, 2007
A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapyFrancis H Grand, Sameena Iqbal, Lingyan Zhang, et al.
Pageof 4